Can we make further impact in 1L? Powering new possibilities in mNSCLC.
img-mobile-range

MONTHS

median OS with current single-agent immunotherapy ± chemotherapy regimens in patients with PD-L1 ≥50%, based on results of clinical trials.2,4,9#

|| Based on ORR from 4 randomized phase 3 studies of 1L mNSCLC in patients without AGAs treated with a PD-1 or PD-L1 inhibitor.9-12

As seen in 243 patients with mNSCLC who initially responded to anti–PD-1 treatment at Memorial Sloan Kettering Cancer Center from April 2011 to December 2017. Acquired resistance was defined as partial or complete response followed by isolated or systemic progression on or before the date of last scan.13

#Based on the 5-year follow-ups of 3 randomized phase 3 studies of 1L mNSCLC in patients without AGAs treated with a PD-1 inhibitor ± chemotherapy.2,4,9

Although immunotherapy ± chemotherapy has revolutionized 1L mNSCLC treatment, achieving or maintaining a durable response remains challenging for many patients
Although immunotherapy ± chemotherapy has revolutionized 1L mNSCLC treatment, achieving or maintaining a durable response remains challenging for many patients

EMERGING POTENTIAL

TROP-2.

EMERGING POTENTIAL

Powering possibilities in mNSCLC with TROP-215

TROP-2.

TROP-2, a proven target in multiple cancers, is a calcium signal transducer involved in several signaling pathways related to:

  • Cell proliferation through cyclins and cyclin-dependent kinases
  • Invasion and metastasis via matrix metalloproteinases and other proteins
  • Cell survival by degradation of FOXO3a

TROP-2 is expressed in 89% to 100% of NSCLC, regardless of tumor histology or presence of actionable alterations.16-18

Mobile/Burden-Callout Copy 2 Ongoing exploration of additional investigational pathways in mNSCLC Other evolving research areas in mNSCLC include but are not limited to cell surface proteins CTLA-4, LAG3, VEGF, and cMET.3,19
Desktop/Burden-Callout Copy 2 Ongoing exploration of additional investigational pathways in mNSCLC Other evolving research areas in mNSCLC include but are not limited to cell surface proteins CTLA-4, LAG3, VEGF, and cMET.3,19

STAY INFORMED

Gilead Oncology is committed to making scientific advancements in lung cancer
Gilead Oncology is committed to making scientific advancements in lung cancer

1L=first line; AGA=actionable genomic alteration; anti–PD-(L)1=anti-programmed cell death protein ligand 1; cMET=mesenchymal-epithelial transition receptor; CTLA-4=cytotoxic T-lymphocyte associated protein 4; FOXO3a=Forkhead Box O3a; GLOBOCAN=Global Cancer Observatory; LAG3=lymphocyte-activation gene 3; mNSCLC=metastatic non-small cell lung cancer; mOS=median overall survival; NSCLC=non-small cell lung cancer; ORR=objective response rate; OS=overall survival; PD-1=programmed cell death protein 1; PD-L1=programmed cell death protein ligand 1; SEER=Surveillance, Epidemiology, and End Results; TROP-2=trophoblast cell surface antigen 2; VEGF=vascular endothelial growth factor.

References:
  1. Akinboro O, Vallejo JJ, Nakajima EC, et al. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis. Abstract presented at: American Society of Clinical Oncology Annual Meeting; June 2022; Chicago, IL.
  2. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992-1998.
  3. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50%. J Clin Oncol. 2021;39(21):2339-2349.
  4. Novello S, Kowalski DM, Luft A, et al. Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41(11):1999-2006.
  5. Kilickap S, Baramidze, A, Sezer A, et al. Cemiplimab monotherapy for first-line treatment of patients with advanced NSCLC with PD-L1 expression of 50% or higher: five-year outcomes of EMPOWER-Lung 1. J Thorac Oncol. 2025;S1556-0864(25)00178-9. doi: 10.1016/j.jtho.2025.03.033
  6. Schabath B, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563-1579.
  7. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
  8. National Cancer Institute: SEER 21. Cancer Stat Facts: Lung and Bronchus Cancer. Accessed March 27, 2026. https://seer.cancer.gov/statfacts/html/lungb.html
  9. de Castro Jr G, Kudaba I, Wu Y-L, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥1% in the KEYNOTE-042 study. J Clin Oncol. 2023;41(11):1986-1991.
  10. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.
  11. Jassem J, de Marinis F, Giaccone G, et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC. J Thorac Oncol. 2021;16(11):1872-1882.
  12. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604.
  13. Memon D, Schoenfeld AJ, Ye D, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42(2):209-224.
  14. Waterhouse D, Lam J, Betts KA, et al. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 2021;156:41-49.
  15. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6(3-4):84-105.
  16. Omori S, Muramatsu K, Kawata T, et al. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments. J Cancer Res Clin Oncol. 2022;148(9):2455-2463.
  17. Mito R, Matsubara E, Komohara Y, et al. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int. 2020;70(5):287-294.
  18. Kuo P, Elboudwarej E, Diehl L, Patel J, Mekan S, Jürgensmeier JM. Trop-2 expression in non-small cell lung carcinoma. Poster presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando, FL.
  19. Meyer ML, Fitzgerald BG, Paz-Ares L, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404(10454):803-822.
TOP

This site is intended for US
healthcare professionals

Proceed to site

You are now
leaving this site